Recurrent PAK2 rearrangements in poroma with folliculo‐sebaceous differentiation
暂无分享,去创建一个
F. Tirode | M. Battistella | S. Mourah | N. Macagno | E. Calonje | T. Kervarrec | D. Pissaloux | A. de la Fouchardière | K. Goto | P. Sohier | F. Jouenne | E. Frouin | A. Osio | B. Cribier | S. Paindavoine | F. Drouot | Agnes Pekar | Evelyn Vanesa Erazo Luna | Flore Delalande | Monique Faisan | P. Sohier
[1] F. Tirode,et al. Distinct regulations driving YAP1 expression loss in poroma, porocarcinoma and RB1‐deficient skin carcinoma , 2023, Histopathology.
[2] R. Penin,et al. Poroma: A Retrospective Series of 80 Patients at a Tertiary Care Hospital. , 2022, Actas dermo-sifiliograficas.
[3] R. Penin,et al. Poroma: A Retrospective Series of 80 Patients at a Tertiary Care Hospital. , 2022, Actas Dermo-Sifiliográficas.
[4] M. Battistella,et al. Recent Advances on Immunohistochemistry and Molecular Biology for the Diagnosis of Adnexal Sweat Gland Tumors , 2022, Cancers.
[5] J. Brognard,et al. New Therapeutic Opportunities for the Treatment of Squamous Cell Carcinomas: A Focus on Novel Driver Kinases , 2021, International journal of molecular sciences.
[6] Z. Dong,et al. CDK12 and PAK2 as novel therapeutic targets for human gastric cancer , 2020, Theranostics.
[7] K. Tsuta,et al. Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma. , 2019, The Journal of clinical investigation.
[8] Steven J. M. Jones,et al. Whole genome and whole transcriptome genomic profiling of a metastatic eccrine porocarcinoma , 2018, npj Precision Oncology.
[9] D. Pissaloux,et al. Cutaneous Melanocytoma With CRTC1-TRIM11 Fusion: Report of 5 Cases Resembling Clear Cell Sarcoma , 2017, The American journal of surgical pathology.
[10] Yungtai Lo,et al. Holocrine Poroma: A Distinctive Adnexal Tumor , 2017, The American Journal of dermatopathology.
[11] K. Hoeflich,et al. p21-Activated Kinase 2 Regulates Endothelial Development and Function through the Bmk1/Erk5 Pathway , 2015, Molecular and Cellular Biology.
[12] R. Xie,et al. Activation of P21-activated protein kinase 2 is an independent prognostic predictor for patients with gastric cancer , 2014, Diagnostic Pathology.
[13] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[14] E. Manser,et al. PAK family kinases , 2012, Cellular logistics.
[15] H. Kutzner,et al. Sebaceous Differentiation in Poroid Neoplasms: Report of 11 Cases, Including a Case of Metaplastic Carcinoma Associated With Apocrine Poroma (Sarcomatoid Apocrine Porocarcinoma) , 2008, The American Journal of dermatopathology.
[16] P. H. Mckee,et al. Eccrine Porocarcinoma (Malignant Eccrine Poroma): A Clinicopathologic Study of 69 Cases , 2001, The American journal of surgical pathology.
[17] E. Alnemri,et al. Cleavage and activation of p21-activated protein kinase gamma-PAK by CPP32 (caspase 3). Effects of autophosphorylation on activity. , 1998, The Journal of biological chemistry.
[18] P. Leboit,et al. Eccrine or apocrine poroma? Six poromas with divergent adnexal differentiation. , 1996, The American Journal of dermatopathology.
[19] D. Hanau,et al. [The infundibular adenoma: a follicular poroma with sebaceous and apocrine differentiation (author's transl)]. , 1981, Annales de dermatologie et de venereologie.